GSK2881078

GSK2881078

Legal status
Legal status	US:Investigational drug
Identifiers
IUPAC name 1-[(2R)-1-methylsulfonylpropan-2-yl]-4-(trifluoromethyl)indole-5-carbonitrile
CAS Number	1539314-06-1
PubChem CID	86709174
ChemSpider	57621607
UNII	47M5ZXU844
Chemical and physical data
Formula	C14H13F3N2O2S
Molar mass	330.33 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](CS(=O)(=O)C)N1C=CC2=C1C=CC(=C2C(F)(F)F)C#N
InChI InChI=1S/C14H13F3N2O2S/c1-9(8-22(2,20)21)19-6-5-11-12(19)4-3-10(7-18)13(11)14(15,16)17/h3-6,9H,8H2,1-2H3/t9-/m1/s1 Key:SKDVMPZQJMZEAC-SECBINFHSA-N

GSK2881078 is a drug which acts as a selective androgen receptor modulator (SARM). It was developed for the prevention of muscle wasting and sarcopenia in elderly people. ^{[1] [2] [3]}

In a phase II trial the drug was shown to be well tolerated and increased muscle strength in men with COPD. ^[4]

See also

• Enobosarm
• JNJ-28330835
• Ligandrol

References

1. Clark RV, Walker AC, Andrews S, Turnbull P, Wald JA, Magee MH (October 2017). "Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women". British Journal of Clinical Pharmacology. 83 (10): 2179–2194. doi: 10.1111/bcp.13316 . PMC   5595940 . PMID   28449232.
2. Neil D, Clark RV, Magee M, Billiard J, Chan A, Xue Z, Russell A (September 2018). "GSK2881078, a SARM, Produces Dose-Dependent Increases in Lean Mass in Healthy Older Men and Women". The Journal of Clinical Endocrinology and Metabolism. 103 (9): 3215–3224. doi: 10.1210/jc.2017-02644 . PMID   29982690.
3. Zierau O, Kolodziejczyk A, Vollmer G, Machalz D, Wolber G, Thieme D, Keiler AM (May 2019). "Comparison of the three SARMs RAD-140, GLPG0492 and GSK-2881078 in two different in vitro bioassays, and in an in silico androgen receptor binding assay". The Journal of Steroid Biochemistry and Molecular Biology. 189: 81–86. doi:10.1016/j.jsbmb.2019.02.014. PMID   30825507. S2CID   72334106.
4. Mohan D, Rossiter H, Watz H, Fogarty C, Evans RA, Man W, et al. (March 2023). "Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial". Thorax. 78 (3): 258–266. doi:10.1136/thorax-2021-218360. PMC   9985744 . PMID   36283827.